Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Evaluate the tolerance of patients with blastomycosis, histoplasmosis, and
sporotrichosis to different doses of itraconazole (R51,211).
II. Determine levels of itraconazole in serum and other body fluids. III. Assess the course
of illness during itraconazole therapy. IV. Determine the dosage of itraconazole that is safe
and well tolerated by 80%-90% of patients and estimate the potential of this dosage for use
in future comparative trials.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Center for Research Resources (NCRR)
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) University of Alabama at Birmingham